Transplant antibody-mediated rejection: guiding effective treatments
The British Kidney Patient Association, UK Transplantation Clinical Study Group and the James Lind Alliance Transplant Priority Setting Partnership highlighted the need for more research on renal transplant rejection. This idea aligned with a clinical trial proposal to assess the efficacy of available treatments for acute antibody-mediated rejection in renal transplantation. TAR:GET-1 (NCT03994783) began as a UK multi-centre randomised controlled trial funded by Kidney Research UK and NIHR Health Technology Assessment Programme. Unfortunately, the trial had to be halted during covid-19, because it was unsafe to give immunosuppressants to vulnerable patients. For various reasons, the research team subsequently decided not to re-open TAR:GET-1 in 2022.